减肥药双雄争霸：诺和诺德惨败礼来，股价崩了！

Core Viewpoint - The pharmaceutical industry is experiencing significant turmoil as Novo Nordisk faces a major stock decline due to its new weight loss drug underperforming compared to Eli Lilly's offering, leading to a substantial market capitalization loss. Group 1: Company Performance - Novo Nordisk's stock plummeted over 16%, reaching its lowest point since June 2021, with a market value of $176.948 billion [2] - Eli Lilly's stock rose by 4.8%, bringing its total market capitalization to $998.6 billion [3] - Novo Nordisk's CagriSema showed a weight loss of 20.2% after 84 weeks, while Eli Lilly's Tirzepatide achieved a 23.6% reduction [5] Group 2: Drug Development and Market Dynamics - CagriSema is a combination drug developed by Novo Nordisk, which includes long-acting amylin analog Cagrilintide and GLP-1 receptor agonist semaglutide [5] - Novo Nordisk submitted a regulatory application for CagriSema to the FDA in December 2022, expecting a decision by the end of 2026 [5] - Eli Lilly's Zepbound has seen explosive demand since its launch, with Q4 revenue in the U.S. reaching $4.2 billion, a 122% increase year-over-year [14] Group 3: Future Outlook - Novo Nordisk anticipates a revenue decline of 5% to 13% for the year, significantly worse than the analyst expectation of a 1.4% drop [9] - The company faces unprecedented pricing pressure, particularly with its flagship drug Wegovy expected to decrease in price in the U.S. [10] - Analysts predict that Eli Lilly's Zepbound will continue to dominate the market, making it difficult for Novo Nordisk to regain market share despite CagriSema's potential [15][16]